Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schmider

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
Biological Psychiatry|February 1, 1997
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoformsL L von Moltke, S X Duan, D J Greenblatt, et al.
Journal of Clinical Pharmacology|September 1, 1996
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agentsL L von Moltke, D J Greenblatt, J Schmider, et al.
Biological Psychiatry|June 2, 1998
The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression testM Deuschle, U Schweiger, U Gotthardt, et al.
Digestive Diseases and Sciences|May 22, 2003
Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosisKai-Wolfgang Roesler, Wolfgang Schmider, Manfred Kist, et al.
Psychopharmacology|August 1, 1997
Human cytochromes mediating N-demethylation of fluoxetine in vitroL L von Moltke, D J Greenblatt, S X Duan, et al.
Psychopharmacology|August 13, 1999
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actionsL L von Moltke, D J Greenblatt, B W Granda, et al.
Pediatric Diabetes|April 12, 2022
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetesMargarita Barrientos-Pérez, Daniel S Hsia, Lance Sloan, et al.
International Journal of Sports Medicine|July 10, 1998
Endurance training and its effect upon the activity of the GH-IGFs system in the elderlyM Deuschle, W F Blum, J Frystyk, et al.
Psychopharmacology|December 1, 1996
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxineL L von Moltke, D J Greenblatt, S X Duan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2026
Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetesRao N V S Mamidi, Mark Peakman, Wolfgang Schmider, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Biological Psychiatry|February 1, 1997
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoformsL L von Moltke, S X Duan, D J Greenblatt, et al.
Journal of Clinical Pharmacology|September 1, 1996
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agentsL L von Moltke, D J Greenblatt, J Schmider, et al.
Biological Psychiatry|June 2, 1998
The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression testM Deuschle, U Schweiger, U Gotthardt, et al.
Digestive Diseases and Sciences|May 22, 2003
Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosisKai-Wolfgang Roesler, Wolfgang Schmider, Manfred Kist, et al.
Psychopharmacology|August 1, 1997
Human cytochromes mediating N-demethylation of fluoxetine in vitroL L von Moltke, D J Greenblatt, S X Duan, et al.
Psychopharmacology|August 13, 1999
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actionsL L von Moltke, D J Greenblatt, B W Granda, et al.
Pediatric Diabetes|April 12, 2022
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetesMargarita Barrientos-Pérez, Daniel S Hsia, Lance Sloan, et al.
International Journal of Sports Medicine|July 10, 1998
Endurance training and its effect upon the activity of the GH-IGFs system in the elderlyM Deuschle, W F Blum, J Frystyk, et al.
Psychopharmacology|December 1, 1996
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxineL L von Moltke, D J Greenblatt, S X Duan, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2026
Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetesRao N V S Mamidi, Mark Peakman, Wolfgang Schmider, et al.
Pageof 14